Bedrijfsoverzicht
Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical entity with a global footprint spanning North America, Europe, India, Russia, and other international markets, delivering solutions through its specialized segments including Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. The company functions within the healthcare sector, specifically categorized under the industry of Drug Manufacturers - Specialty & Generic, a classification that signifies its focus on both branded and unbranded medicinal products alongside active ingredient production. This organization employs a workforce of 27,811 individuals to support its extensive operations and supply chain logistics across diverse geographic regions. With a market capitalization of $11.11B and annual revenue reaching $345.83B, the company demonstrates a significant scale that positions it as a major player in the global pharmaceutical landscape, although the revenue figure presented suggests a valuation context that requires careful interpretation against the stated market cap. The disparity between the reported revenue of $345.83B and the market cap of $11.11B indicates a specific accounting or reporting context where the revenue metric may reflect consolidated global sales including intercompany transactions or specific fiscal periods not fully aligned with the current market valuation, highlighting a structural characteristic of the entity's financial reporting versus its equity value.
Financiële gezondheid
The company reported revenue of $345.83B and net income of $56.59B for the trailing twelve months, with an EBITDA of $84.79B, revealing a substantial gap between top-line revenue and net profit that underscores a complex cost structure involving high operating expenses, R&D investments, and potentially significant non-operating costs or consolidation adjustments. Free cash flow stands at $13.47B, which provides the company with considerable financial flexibility to fund capital expenditures, pursue strategic acquisitions, or manage liquidity requirements without relying heavily on external financing. The gross margin is recorded at 55.2%, indicating strong pricing power or high-margin product mixes in certain segments, while the operating margin and profit margin are both stated at 16.4%, suggesting that operating expenses consume a significant portion of the gross profit before arriving at the bottom line. On the balance sheet, cash holdings total $82.59B against total debt of $67.73B, resulting in a debt-to-equity ratio of 18.03, which technically indicates a leveraged position if interpreted strictly by the ratio, yet the absolute net cash position of approximately $14.86B suggests a highly conservative liquidity profile that mitigates actual solvency risk. The current ratio of 1.88 indicates robust short-term liquidity, confirming that the company possesses sufficient current assets to cover its current liabilities comfortably. Return on Equity is 16.1% and Return on Assets is 8.0%, metrics that reveal management's effectiveness in generating returns relative to shareholder equity and the total asset base, respectively, though the high leverage ratio complicates the direct interpretation of asset efficiency in traditional terms.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is 18.23, while the forward P/E stands at 23.75, implying that the market expects earnings to decline or grow at a rate that results in a higher valuation multiple in the future, which often signals anticipated headwinds in earnings growth rather than a standard premium for expansion. The price-to-book ratio is 2.78, indicating that the market values the company at a significant premium over its book value, reflecting intangible assets, brand equity, or growth expectations that are not captured on the historical balance sheet. Alternative valuation metrics include a price-to-sales ratio of 0.03 and an EV/EBITDA of -0.01, which suggest extreme valuation compression or data anomalies where the enterprise value is nearly equal to earnings, potentially resulting from negative earnings adjustments or specific accounting treatments that distort traditional multiple comparisons. The stock has traded between a 52-week high of $16.17 and a 52-week low of $12.81, and without the current share price explicitly defined in the provided facts, the relative positioning within this range cannot be numerically calculated, but the range itself establishes the recent volatility boundaries for the security. The beta value is 0.30, which indicates that the stock price exhibits significantly lower volatility relative to the broader market, behaving as a defensive instrument that is less sensitive to general market fluctuations compared to high-beta equities.
Growth & Income
Revenue growth over the past year is 4.4%, whereas earnings growth is -14.3%, indicating that earnings are growing significantly slower than revenue, specifically contracting while sales expand, which implies that cost pressures, margin compression, or one-time charges are outweighing top-line expansion. The company offers a dividend yield of 0.7% with a payout ratio of 11.8%, demonstrating a highly sustainable dividend policy where the payout is a small fraction of earnings, leaving ample room for retention of earnings to fund operations or strategic initiatives. Given the negative earnings growth, the dividend sustainability is further reinforced by the massive cash reserves and the low payout ratio, ensuring that the yield is not at risk of being cut despite the decline in net income. The overall growth and income profile presents a scenario of modest revenue expansion coupled with declining earnings and a minimal but stable dividend yield, reflecting a mature business phase where capital allocation focuses on cash preservation rather than aggressive reinvestment for high-growth yields.